Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Chemotherapy and Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Stomach Who Have Undergone Surgery
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- Radiation Therapy Oncology Group
- Registration Number
- NCT00011960
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸John F. Kennedy Medical Center, Edison, New Jersey, United States
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00007982
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 61
- Registration Number
- NCT00030745
- Locations
- 🇨🇭
UniversitaetsSpital, Zurich, Switzerland
Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 84
- Registration Number
- NCT00023660
- Locations
- 🇺🇸
Akron General Medical Center, Akron, Ohio, United States
🇺🇸Akron City Hospital - Summa Health System, Akron, Ohio, United States
🇺🇸Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 97
- Registration Number
- NCT00033657
- Locations
- 🇺🇸
CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸CCOP - Christiana Care Health Services, Newark, Delaware, United States
ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.
- Conditions
- First Posted Date
- 2003-01-14
- Last Posted Date
- 2006-07-20
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00051506
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Charleston, South Carolina, United States
Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT00001450
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00001499
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
- Conditions
- First Posted Date
- 2002-07-04
- Last Posted Date
- 2007-03-15
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00040625
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Basking Ridge, New Jersey, United States
🇸🇦For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Jeddah, Saudi Arabia
🇪🇬"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.", Cairo, Egypt
Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 74
- Registration Number
- NCT00001569
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.